Human insulin receptor substrate-2 (IRS-2) is a primary progesterone response gene

Molecular Endocrinology

Volumn 13, Issue 3, 1999, Pages 485-494

  Vaßen, Lothar ^a   Wegrzyn, Wojciech ^a   Klein Hitpass, Ludger ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INSULIN; INSULIN RECEPTOR; MIFEPRISTONE; PROGESTERONE; SOMATOMEDIN C;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; HORMONAL REGULATION; HORMONE ACTION; HORMONE RESPONSE; HORMONE RESPONSIVE ELEMENT; HUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

EID: 0032963274     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.13.3.0256     Document Type: Article

References (32)

1. 1. Kester HA, van der Leede BM, van der Saag PT, van den Burg B 1997 Novel progesterone target genes identified by an improved differential display technique suggest that progestin-induced growth inhibition of breast cancer cells coincides with enhancement of differentiation. J Biol Chem 272:16637-16643
2. 2. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schütz G, Umesono K, Blumberg B, Kästner P, Mark M, Chambon P 1995 The nuclear receptor superfamily: the second decade. Cell 83:835-839
3. 3. Strähle U, Klock G, Schütz G 1987 A DNA sequence of 15 base pairs is sufficient to mediate both glucocorticoid and progesterone induction of gene expression. Proc Natl Acad Sci USA 84:7871-7875
4. 4. von der Ahe D, Janich S, Scheidereit C, Renkawitz R, Schütz G, Beato M 1985 Glucocorticoid and progesterone receptors bind to the same sites in two hormonally regulated promoters. Nature 313:706-709
5. 5. Gaillard RC, Riondel A, Muller AF, Herrmann W, Baulieu EE 1984 RU486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. Proc Natl Acad Sci USA 81:3879-3882
6. 6. Bakker GH, Setyono-Han B, Portengen H, De JF, Foekens JA, Klijn JG 1990 Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 37:789-794
7. 7. Klijn JG, De JF, Bakker GH, Lamberts SW, Rodenburg CJ, Alexieva-Figusch J 1989 Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res 49:2851-2856
8. 8. Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP 1993 The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci USA 90:4441-4445
9. 9. Kahmann S, Vassen L, Klein-Hitpass L 1998 Synergistic enhancement of PRB-mediated RU486 and R5020 agonist activities through cyclic adenosine 3′,5′-monophosphate represents a delayed primary response. Mol Endocrinol 12:278-289
10. 10. Nordeen SK, Bona BJ, Beck CA, Edwards DP, Borror KC, DeFranco DB 1995 The two faces of a steroid antagonist: when an antagonist isn't. Steroids 60:97-104
11. 11. Sartorius CA, Tung L, Takimoto GS, Horwitz KB 1993 Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J Biol Chem 268:9262-9266
12. 12. Tung L, Mohamed MK, Hoeffler JP, Takimoto GS, Horwitz KB 1993 Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol 7:1256-1265
13. 13. Horwitz KB, Tung L, Takimoto GS 1995 Novel mechanisms of antiprogestin action. J Steroid Biochem Mol Biol 53:9-17
14. 14. Waters SB, Pessin JE 1997 Insulin receptor substrate 1 and 2 IRS1 and IRS 2: what a tangled web we weave. Trends Cell Biol 6:1-4
15. 15. White MF 1997 The insulin signalling system and the IRS proteins. Diabetologia 40:52-17
16. 16. Yenush L, White MF 1997 The IRS-signalling system during insulin and cytokine action. Bioessays 19:491-500
17. 17. Sun XJ, Pons S, Wang LM, Zhang Y, Yenush L, Burks D, Myers Jr MG, Glasheen E, Copeland NG, Jenkins NA, Pierce JH, White MF 1997 The IRS-2 gene on murine chromosome 8 encodes a unique signaling adapter for insulin and cytokine action. Mol Endocrinol 11:251-262
18. 18. Sun XJ, Wang LM, Zhang Y, Yenush L, Myers Jr MG, Glasheen E, Lane WS, Pierce JH, White MF 1995 Role of IRS-2 in insulin and cytokine signalling. Nature 377:173-177
19. 19. He W, Craparo A, Zhu Y, O'Neill TJ, Wang LM, Pierce JH, Gustafson TA 1996 Interaction of insulin receptor substrate-2 IRS-2 with the insulin and insulin-like growth factor I receptors. Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2. J Biol Chem 271:11641-11645
20. 20. Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA, Cahill DA, Goldstein BJ, White MF 1991 Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352:73-77
21. 21. Lavan BE, Lane WS, Lienhard GE 1997 The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J Biol Chem 272:11439-11443
22. 22. Lavan BE, Fantin VR, Chang ET, Lane WS, Keller SR, Lienhard GE 1997 A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J Biol Chem 272:21403-21407
23. 23. Ogihara T, Isobe T, Ichimura T, Taoka M, Funaki M, Sakoda H, Onishi Y, Inukai K, Anai M, Fukushima Y, Kikuchi M, Yazaki Y, Oka Y, Asano T 1997 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J Biol Chem 272:25267-25274
24. 24. Araki E, Lipes MA, Patti ME, Brüning JC, Haag BLI II, Johnson RS, Kahn CR 1994 Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186-190
25. 25. Kadowaki T, Tamemoto H, Tobe K, Terauchi Y, Ueki K, Kaburagi Y, Yamauchi T, Satoh S, Sekihara H, Aizawa S, Yazaki Y 1996 Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1 and identification of insulin receptor substrate-2. Diabet Med 13:103-1088
26. 26. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI, Bonner-Weir S, White MF 1998 Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391:900-904
27. 27. Brüning JC, Winnay J, Cheatham B, Kahn CR 1997 Differential signaling by insulin receptor substrate 1 IRS-1 and IRS- 2 in IRS-1-deficient cells. Mol Cell Biol 17:1513-1521
28. 28. Bernal D, Almind K, Yenush L, Ayoub M, Zhang Y, Rosshani L, Larsson C, Pedersen O, White MF 1998 Insulin receptor substrate-2 amino acid polymorphisms are not associated with random type 2 diabetes among Caucasians. Diabetes 47:976-979
29. 29. Dey BR, Frick K, Lopaczynski W, Nissley SP, Furlanetto RW 1996 Evidence for the direct interaction of the insulin-like growth factor I receptor with IRS-1, Shc, and Grb10. Mol Endocrinol 10:631-641
30. 30. Bauer D, Müller H, Reich J, Riedel H, Ahrenkiel V, Warthoe P, Strauss M 1993 Identification of differentially expressed mRNA species by an improved display technique DDRT-PCR. Nucleic Acids Res 21:4272-4280
31. 31. Araki E, Sun XJ, Haag BL, Chuang LM, Zhang Y, Yang-Feng TL, White MF, Kahn CR 1993 Human skeletal muscle insulin receptor substrate-1. Characterization of the cDNA, gene, and chromosomal localization. Diabetes 42:1041-1054
32. 32. Corpet F 1988 Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16:10881-10890